Tasquinimod-d3

Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528) . Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].

Product Specifications

CAS Number

[1416701-99-9]

Product Name Alternative

ABR-215050-d3

UNSPSC

12352005

Target

HDAC; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.34

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C1=CC=C(C=C1)C(F)(F)F)C([2H])([2H])[2H])C2=C(C3=C(C=CC=C3OC)N(C2=O)C)O

Molecular Formula

C20H14D3F3N2O4

Molecular Weight

409.37

References & Citations

[1]Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73 (4) :1386-99.|[2]Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.|[3]Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep 30;5 (18) :8093-106.